378 results on '"Munzone, E"'
Search Results
2. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
3. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
4. CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
5. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
6. Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
7. Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
8. Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
9. Treatment of Central Nervous System Involvement
10. 212P Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
11. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99
12. CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
13. P003 ROSE trial: A prospective non-interventional study to assess the quality of life (QoL) of premenopausal patients with early breast cancer receiving triptorelin as ovarian function suppression
14. Usability Testing of a New Digital Integrated Health Ecosystem (PainRELife) for the Clinical Management of Chronic Pain in Patients with Early Breast Cancer: Protocol for a Pilot Study
15. Real-world use of multigene signatures in early breast cancer: the experience by the Lombardy Genomic Assays for Breast Cancer Working Group
16. Development and psychometric testing of a breast cancer patient-profiling questionnaire
17. 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
18. 341MO Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis
19. Pegylated liposomal doxorubicin (Caelyx®) as adjuvant treatment in early-stage luminal b-like breast cancer: A feasibility phase II trial
20. Ten-year outcome results of cT4 breast cancer after neoadjuvant treatment
21. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
22. Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
23. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
24. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
25. Outcome and clinical–biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases
26. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
27. Should liver metastases of breast cancer be biopsied to improve treatment choice?
28. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
29. Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”
30. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project
31. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report
32. Management of breast cancer patients during the peak of the COVID 19 pandemic
33. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
34. Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
35. Bringing onco?innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
36. 1871P The PainRELife ecosystem: A new aid for improving clinical care and shared decision-making in breast cancer patients with chronic pain
37. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
38. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
39. Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway
40. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
41. Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-β) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery
42. Breast cancer vaccines: a clinical reality or fairy tale?
43. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
44. CMF revisited in the 21st century
45. 155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
46. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis
47. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
48. 273 (PB-097) Poster - Real-world use of multigene signatures in early breast cancer: the experience by the Lombardy Genomic Assays for Breast Cancer Working Group
49. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
50. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.